Xtandi vs Calquence
Side-by-side drug price comparison from Medicare Part D data
Verdict
Xtandi costs 8% less per claim than Calquence ($9331.00 vs $10105.00). Xtandi has a generic alternative available. Total Medicare spending: Xtandi at $4.1B vs Calquence at $2.9B.
| Metric | Xtandi | Calquence |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $9,331* | $10,105 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $4.1B | $2.9B |
| Total Claims | 438,000 | 286,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 9.4%* | 34.2% |
| Generic Available | Yes | Yes |
| Condition | Cancer | Cancer |
| Total Beneficiaries | 46,000 | 28,000 |
Xtandi costs 8% less per claim than Calquence ($9331.00 vs $10105.00). Xtandi has a generic alternative available. Total Medicare spending: Xtandi at $4.1B vs Calquence at $2.9B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Xtandi and Calquence. What follows is the interpretation — which specific axes carry the most weight for Xtandi versus Calquence, and which differences are large enough to influence a real decision.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.